PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis
NASDAQ:PRVA - Nasdaq - US74276R1023 - Common Stock - Currency: USD
Overall PRVA gets a fundamental rating of 4 out of 10. We evaluated PRVA against 105 industry peers in the Health Care Providers & Services industry. No worries on liquidiy or solvency for PRVA as it has an excellent financial health rating, but there are worries on the profitability. PRVA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PRVA had positive earnings in the past year.
In the past year PRVA had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: PRVA reported negative net income in multiple years.
In the past 5 years PRVA always reported a positive cash flow from operatings.
1.2 Ratios
PRVA's Return On Assets of 1.27% is in line compared to the rest of the industry. PRVA outperforms 52.38% of its industry peers.
The Return On Equity of PRVA (2.26%) is comparable to the rest of the industry.
With a Return On Invested Capital value of 1.65%, PRVA perfoms like the industry average, outperforming 43.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.27% | ||
| ROE | 2.26% | ||
| ROIC | 1.65% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRVA's Profit Margin of 0.83% is in line compared to the rest of the industry. PRVA outperforms 54.29% of its industry peers.
In the last couple of years the Profit Margin of PRVA has declined.
With a Operating Margin value of 0.98%, PRVA perfoms like the industry average, outperforming 41.90% of the companies in the same industry.
In the last couple of years the Operating Margin of PRVA has declined.
The Gross Margin of PRVA (10.19%) is worse than 77.14% of its industry peers.
PRVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.98% | ||
| PM (TTM) | 0.83% | ||
| GM | 10.19% |
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
The number of shares outstanding for PRVA has been increased compared to 1 year ago.
Compared to 5 years ago, PRVA has more shares outstanding
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 5.07 indicates that PRVA is not in any danger for bankruptcy at the moment.
PRVA has a Altman-Z score of 5.07. This is amongst the best in the industry. PRVA outperforms 86.67% of its industry peers.
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.07 |
ROIC/WACC0.18
WACC8.98%
2.3 Liquidity
A Current Ratio of 1.86 indicates that PRVA should not have too much problems paying its short term obligations.
PRVA has a Current ratio of 1.86. This is in the better half of the industry: PRVA outperforms 69.52% of its industry peers.
A Quick Ratio of 1.86 indicates that PRVA should not have too much problems paying its short term obligations.
PRVA has a Quick ratio of 1.86. This is in the better half of the industry: PRVA outperforms 70.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.86 | ||
| Quick Ratio | 1.86 |
3. Growth
3.1 Past
PRVA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.11%.
PRVA shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.43% yearly.
PRVA shows a small growth in Revenue. In the last year, the Revenue has grown by 4.74%.
PRVA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.17% yearly.
EPS 1Y (TTM)-42.11%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%50%
Revenue 1Y (TTM)4.74%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%4.74%
3.2 Future
PRVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 61.98% yearly.
Based on estimates for the next years, PRVA will show a decrease in Revenue. The Revenue will decrease by -0.38% on average per year.
EPS Next Y129.34%
EPS Next 2Y86.18%
EPS Next 3Y61.98%
EPS Next 5YN/A
Revenue Next Year10.88%
Revenue Next 2Y10.79%
Revenue Next 3Y11.02%
Revenue Next 5Y-0.38%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 206.45, which means the current valuation is very expensive for PRVA.
PRVA's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of PRVA to the average of the S&P500 Index (27.63), we can say PRVA is valued expensively.
A Price/Forward Earnings ratio of 90.02 indicates a quite expensive valuation of PRVA.
PRVA's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 20.85. PRVA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 206.45 | ||
| Fwd PE | 90.02 |
4.2 Price Multiples
62.86% of the companies in the same industry are cheaper than PRVA, based on the Enterprise Value to EBITDA ratio.
PRVA's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. PRVA is cheaper than 62.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.21 | ||
| EV/EBITDA | 93.35 |
4.3 Compensation for Growth
PRVA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as PRVA's earnings are expected to grow with 61.98% in the coming years.
PEG (NY)1.6
PEG (5Y)27.77
EPS Next 2Y86.18%
EPS Next 3Y61.98%
5. Dividend
5.1 Amount
PRVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22.71
-0.97 (-4.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.73%
Inst Owner Change0.07%
Ins Owners6.04%
Ins Owner Change1.19%
Market Cap2.75B
Analysts84.83
Price Target30.6 (34.74%)
Short Float %3.84%
Short Ratio5.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.76%
Min EPS beat(2)-40.79%
Max EPS beat(2)-38.73%
EPS beat(4)0
Avg EPS beat(4)-43.66%
Min EPS beat(4)-58.84%
Max EPS beat(4)-36.27%
EPS beat(8)2
Avg EPS beat(8)-0.32%
EPS beat(12)5
Avg EPS beat(12)82.75%
EPS beat(16)9
Avg EPS beat(16)66.73%
Revenue beat(2)2
Avg Revenue beat(2)4.7%
Min Revenue beat(2)1.48%
Max Revenue beat(2)7.92%
Revenue beat(4)4
Avg Revenue beat(4)4.12%
Min Revenue beat(4)1.03%
Max Revenue beat(4)7.92%
Revenue beat(8)7
Avg Revenue beat(8)2.33%
Revenue beat(12)7
Avg Revenue beat(12)-11.18%
Revenue beat(16)10
Avg Revenue beat(16)-9.66%
PT rev (1m)4.86%
PT rev (3m)14.19%
EPS NQ rev (1m)7.56%
EPS NQ rev (3m)-9.23%
EPS NY rev (1m)-3.89%
EPS NY rev (3m)-3.82%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-1.05%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)-0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 206.45 | ||
| Fwd PE | 90.02 | ||
| P/S | 1.59 | ||
| P/FCF | 25.21 | ||
| P/OCF | 25.21 | ||
| P/B | 4.34 | ||
| P/tB | 7.18 | ||
| EV/EBITDA | 93.35 |
EPS(TTM)0.11
EY0.48%
EPS(NY)0.25
Fwd EY1.11%
FCF(TTM)0.9
FCFY3.97%
OCF(TTM)0.9
OCFY3.97%
SpS14.31
BVpS5.24
TBVpS3.16
PEG (NY)1.6
PEG (5Y)27.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.27% | ||
| ROE | 2.26% | ||
| ROCE | 2.47% | ||
| ROIC | 1.65% | ||
| ROICexc | 5.8% | ||
| ROICexgc | N/A | ||
| OM | 0.98% | ||
| PM (TTM) | 0.83% | ||
| GM | 10.19% | ||
| FCFM | 6.29% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-10.22%
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
F-Score6
Asset Turnover1.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 59.59 | ||
| Cash Conversion | 450.65% | ||
| Profit Quality | 759.69% | ||
| Current Ratio | 1.86 | ||
| Quick Ratio | 1.86 | ||
| Altman-Z | 5.07 |
F-Score6
WACC8.98%
ROIC/WACC0.18
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.11%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%50%
EPS Next Y129.34%
EPS Next 2Y86.18%
EPS Next 3Y61.98%
EPS Next 5YN/A
Revenue 1Y (TTM)4.74%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%4.74%
Revenue Next Year10.88%
Revenue Next 2Y10.79%
Revenue Next 3Y11.02%
Revenue Next 5Y-0.38%
EBIT growth 1Y-17.64%
EBIT growth 3YN/A
EBIT growth 5Y1.07%
EBIT Next Year504.46%
EBIT Next 3Y103.45%
EBIT Next 5Y62.91%
FCF growth 1Y35.46%
FCF growth 3Y26.09%
FCF growth 5Y42.42%
OCF growth 1Y35.28%
OCF growth 3Y25.67%
OCF growth 5Y35.01%